SHCBP1 is a novel target and exhibits tumor‑promoting effects in gastric cancer

Dong, Yadong; Yuan, Yifang; Yu, Haibo; Tian, Guangjin; Li, Deyu

doi:10.3892/or.2018.6952

Cited by 14 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the bioinformatics analysis of a large number of glioma specimens, we found that PART1 and hsa-miRNA-429 could regulate SHCBP1 expression and that SHCBP1 can be used as a molecular biomarker to judge the prognosis of glioma patients. Previous studies have found that SHCBP1 acts as a cancer-promoting gene in a variety of tumors [19][20][21][22][23], which is consistent with our findings. We also discovered multiple tumor-associated signaling pathways, such as cell cycle and DNA replication, that may lead to glioma development.…”

Section: Discussionsupporting

confidence: 93%

“…hsa-miRNA-429 plays an inhibitory role in a number of tumors [39][40][41], including glioma [42][43][44]. SHCBP1 is involved in the development of hepatocellular carcinoma [21], glioma [19], breast cancer [22], and gastric cancer [23]. However, the lncRNAs and miRNAs with which SHCBP1 interacts and whether it could be used as a prognostic molecular biomarker had been unknown.…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that SHCBP1 plays a role in tumor development that may be related to activation of the FGF [18], NF-κB [19], and/or TGF-β1/Smad signaling pathways [20]. Studies have also shown that SHCBP1 is involved in the development of various tumors such as hepatocellular carcinoma [21], glioma [19], breast cancer [22], and gastric cancer [23].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PART1 and hsa‐miR‐429‐Mediated SHCBP1 Expression Is an Independent Predictor of Poor Prognosis in Glioma Patients

Xuan¹,

Jin²,

Wang³

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Gliomas are the most common primary brain tumors. Because of their high degree of malignancy, patient survival rates are unsatisfactory. Therefore, exploring glioma biomarkers will play a key role in early diagnosis, guiding treatment, and monitoring the prognosis of gliomas. We found two lncRNAs, six miRNAs, and nine mRNAs that were differentially expressed by analyzing genomic data of glioma patients. The diagnostic value of mRNA expression levels in gliomas was determined by receiver operating characteristic (ROC) curve analysis. Among the nine mRNAs, the area under the ROC curve values of only CEP55 and SHCBP1 were >0.7, specifically 0.834 and 0.816, respectively. Additionally, CEP55 and SHCBP1 were highly expressed in glioma specimens and showed increased expression according to the glioma grade, and outcomes of high expression patients were poor. CEP55 was enriched in the cell cycle, DNA replication, mismatch repair, and P53 signaling pathway. SHCBP1 was enriched in the cell cycle, DNA replication, ECM receptor interaction, and P53 signaling pathway. Age, grade, IDH status, chromosome 19/20 cogain, and SHCBP1 were independent factors for prognosis. Our findings suggest the PART1-hsa-miR-429-SHCBP1 regulatory network plays an important role in gliomas.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

PART1 and hsa‐miR‐429‐Mediated SHCBP1 Expression Is an Independent Predictor of Poor Prognosis in Glioma Patients

Xuan¹,

Jin²,

Wang³

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…SHCBP1 expression was higher in breast cancer compared with adjusted tissue and it correlated with worse cancer stage and poor survival [72]. SHCBP1 was shown to promote gastric cancer [73]. SHCBP1 is upregulated in lung cancer cell lines and plays a role in apoptosis [74].…”

Section: Discussionmentioning

confidence: 99%

A Novel 4-gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer

Oshi

Katsuta

Yan

et al. 2020

Cancers

View full text Add to dashboard Cite

We generated a 4-gene score with genes upregulated in LM2-4, a metastatic variant of MDA-MB-231 (DOK 4, HCCS, PGF, and SHCBP1) that was strongly associated with disease-free survival (DFS) in TCGA cohort (hazard ratio [HR]>1.2, p < 0.02). The 4-gene score correlated with overall survival of TCGA (HR = 1.44, p < 0.001), which was validated with DFS and disease-specific survival of METABRIC cohort. The 4-gene score was able to predict worse survival or clinically aggressive tumors, such as high Nottingham pathological grade and advanced cancer staging. High score was associated with worse survival in the hormonal receptor (HR)-positive/Her2-negative subtype. High score enriched cell proliferation-related gene sets in GSEA. The score was high in primary tumors that originated, in and metastasized to, brain and lung, and it predicted worse progression-free survival for metastatic tumors. Good tumor response to neoadjuvant chemotherapy or hormonal therapy was accompanied by score reduction. High scores were also predictive of response to neoadjuvant chemotherapy for HR-positive/Her2-negative subtype. High score tumors had increased expression of T cell exhaustion marker genes, suggesting that the score may also be a biomarker for immunotherapy response. Our novel 4-gene score with both prognostic and predictive values may, therefore, be clinically useful particularly in HR-positive breast cancer.

show abstract

“…In gastric cancer, SHCBP1 suppressed apoptotic and promoted cell cycle progression which accelerated tumor growth and invasiveness. 31 .…”

Section: Overexpression Of Bub1b Cdk1 Ccna2mentioning

confidence: 99%

Identify key genes and pathways in pancreatic ductal adenocarcinoma via bioinformatics analysis

Luo¹,

Chen²,

Pan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Pancreatic cancer has many pathologic types, among which pancreatic ductal adenocarcinoma (PDAC) is the most common one. Bioinformatics has become a very common tool for the selection of potentially pathogenic genes. Methods: Three data sets containing the gene expression profiles of PDAC were downloaded from the gene expression omnibus (GEO) database. The limma package of R language was utilized to explore the differentially expressed genes (DEGs). To analyze functions and signaling pathways, the Database Visualization and Integrated Discovery (DAVID) was used. To visualize the protein-protein interaction (PPI) of the DEGs ,Cytoscape was performed under the utilization of Search Tool for the Retrieval of Interacting Genes (STRING). With the usage of the plug-in cytoHubba in cytoscape software, the hub genes were found out. To verify the expression levels of hub genes, Gene Expression Profiling Interactive Analysis (GEPIA) was performed. Last but not least, UALCAN analysis online tool was implemented to analyze the overall survival. Results: The 376 DEGs were highly enriched in biological processes including signal transduction, apoptotic process and several pathways, mainly associated with Protein digestion and absorption and Pancreatic secretion pathway. The expression levels of nucleolar and spindle associated protein 1 (NUSAP1) and SHC binding and spindle associated 1 (SHCBP1) were discovered highly expressed in pancreatic ductal adenocarcinoma tissues. NUSAP1 and SHCBP1 had a high correlation with prognosis. Conclusions: The findings of this bioinformatics analysis indicate that NUSAP1 and SHCBP1 may be key factors in the prognosis and treatment of pancreatic cancer.

show abstract

SHCBP1 is a novel target and exhibits tumor‑promoting effects in gastric cancer

Cited by 14 publications

References 24 publications

PART1 and hsa‐miR‐429‐Mediated SHCBP1 Expression Is an Independent Predictor of Poor Prognosis in Glioma Patients

PART1 and hsa‐miR‐429‐Mediated SHCBP1 Expression Is an Independent Predictor of Poor Prognosis in Glioma Patients

A Novel 4-gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer

Identify key genes and pathways in pancreatic ductal adenocarcinoma via bioinformatics analysis

Contact Info

Product

Resources

About